Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1/2023

Open Access 01-12-2023 | Osteoporosis | Original Article

A Delphi consensus on the management of Spanish patients with osteoporosis at high risk of fracture: OSARIDELPHI study

Authors: Luis Arboleya, Jose Manuel Cancio-Trujillo, Celia Chaves, Enric Duaso-Magaña, Manuel Mesa-Ramos, Jose Manuel Olmos

Published in: Archives of Osteoporosis | Issue 1/2023

Login to get access

Abstract

Summary

The OSARIDELPHI study evaluated the level of agreement between specialists in osteoporosis regarding the management of patients with high-risk fractures in Spain. The results provide expert-based recommendations for prevention, diagnosis, and treatment related to fracture risk. Therefore, the study facilitates clinical decision-making for managing this patient’s profile.

Purpose

To evaluate the level of agreement between specialists in osteoporosis regarding the management of patients with high-risk fractures in Spain.

Methods

A two-round Delphi study was performed using an online survey. In round 1, panel members rated their level of agreement with assessments on a 9-point Likert scale. Item selection was based on acceptance by ≥ 66.6% of panel experts and the agreement of the scientific committee. In round 2, the same panelists evaluated non-consensus items in round 1.

Results

A total of 80 panelists participated in round 1; of these, 78 completed the round 2 survey. In round 1, 122 items from 4 dimensions (definition of fracture risk: 11 items, prevention and diagnosis: 38 items, choice of treatment: 24 items, and treatment-associated quality of life: 49 items) were evaluated. The consensus was reached for 90 items (73.8%). Panelists agreed that categorizing high risk, very high risk, or imminent risk determines secondary prevention actions (97.5%). Experts agreed that treatment with bone-forming drugs should be considered in case of a very high risk of fracture, and a sequential change to antiresorptive drugs should be made after 1–2 years (97.5%). Panelists also recommended corrective action plans for non-adherent patients to improve adherence (97.5%). A total of 131 items were finally accepted after round 2.

Conclusion

This Delphi study provides expert-based recommendations on clinical decision-making for managing patients with osteoporosis at high risk of fracture.
Appendix
Available only for authorised users
Literature
1.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMed
2.
Sanchez-Riera L, Wilson N, Kamalaraj N et al (2010) Osteoporosis and fragility fractures. Best Pract Res Clin Rheumatol 24:793–810PubMed
3.
González Y, Sicras A, Larraínzar R, Sorio F, Canals L, Lizán L, Calvo E (2014) Estimación de los costes sanitarios relacionados con las fracturas osteoporóticas en pacientes posmenopáusicas en España. PharmacoEconomics Spanish Res Articles 12:1–9
4.
Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136PubMedPubMedCentral
5.
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82PubMedPubMedCentral
6.
Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgström F, Kanis JA (2022) Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos 17:23PubMedPubMedCentral
7.
Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937–948PubMedPubMedCentral
8.
Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034PubMedPubMedCentral
9.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMed
10.
Papaioannou A, Kennedy C (2015) Diagnostic criteria for osteoporosis should be expanded. Lancet Diabetes Endocrinol 3:234–236PubMedPubMedCentral
11.
Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:1765–1769PubMed
12.
van Geel TA, Huntjens KM, van den Bergh JP, Dinant GJ, Geusens PP (2010) Timing of subsequent fractures after an initial fracture. Curr Osteoporos Rep 8:118–122PubMedPubMedCentral
13.
14.
González López-Valcárcel B, Sosa Henríquez M (2013) Estimate of the 10-year risk of osteoporotic fractures in the Spanish population. Med Clin 140:104–109
15.
16.
Herrera A, Carpintero P, Fernandez-Perez C, Hernandez-Vaquero D, Martinez AA, Suso S (2011) Secondary prevention in osteoporotic fractures. The GIOS project. Medicina clinica 136:50–55PubMed
17.
Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL (2005) Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 20:557–563PubMed
18.
Sanfélix-Genovés J, Reig-Molla B, Sanfélix-Gimeno G, Peiró S, Graells-Ferrer M, Vega-Martínez M, Giner V (2010) The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study). Bone 47:610–616PubMed
19.
Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623–2637PubMed
20.
Naranjo A, Molina A, Quevedo A, Rubino FJ, Sanchez-Alonso F, Rodriguez-Lozano C, Ojeda S (2021) Fracture liaison service model: treatment persistence 5 years later. Arch Osteoporos 16:60PubMed
21.
Naranjo A, Ojeda S, Giner M et al (2020) Best practice framework of fracture liaison services in Spain and their coordination with primary care. Arch Osteoporos 15:020–0693
22.
Noordin S, Allana S, Masri BA (2018) Establishing a hospital based fracture liaison service to prevent secondary insufficiency fractures. Int J Surg 54:328–332PubMed
23.
Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12PubMed
24.
Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32:1951–1960PubMed
25.
26.
Yeh JS, Van Hoof TJ, Fischer MA (2016) Key features of academic detailing: development of an expert consensus using the delphi method. Am Health Drug Benefits 9:42–50PubMedPubMedCentral
27.
Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32:1008–1015PubMed
28.
James D, Warren-Forward H (2015) Research methods for formal consensus development. Nurse Res 22:35–40PubMed
29.
Keeney S, Hasson F, McKenna H (2006) Consulting the oracle: ten lessons from using the Delphi technique in nursing research. J Adv Nurs 53:205–212PubMed
30.
Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44PubMed
31.
Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187–196PubMed
32.
Curtis EM, Reginster JY, Al-Daghri N et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34:695–714PubMedPubMedCentral
33.
Cummings SR, Cosman F, Lewiecki EM et al (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res 32:3–10PubMed
34.
McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775–791PubMed
35.
Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240PubMed
36.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427PubMed
37.
Barrionuevo P, Kapoor E, Asi N et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623–1630PubMed
38.
Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1–8PubMed
39.
Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957PubMedPubMedCentral
40.
Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA (2016) Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) study randomized controlled trial. J Clin Densitom 19:346–351PubMed
41.
Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202PubMed
42.
Kanis JA, Cooper C, Rizzoli R, Reginster JY (2018) Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int 29:1505–1510PubMedPubMedCentral
43.
Elbers LPB, Raterman HG, Lems WF (2021) Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81:1645–1655PubMedPubMedCentral
44.
Javaid MK, Kyer C, Mitchell PJ et al (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool. Osteoporos Int 26:2573–2578PubMed
45.
Javaid MK (2021) Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures. Aging Clin Exp Res 33:2061–2067PubMedPubMedCentral
46.
Barton DW, Piple AS, Smith CT, Moskal SA, Carmouche JJ (2021) The clinical impact of fracture liaison services: a systematic review. Geriatr Orthop Surg Rehabil 12:2151459320979978PubMedPubMedCentral
Metadata
Title
A Delphi consensus on the management of Spanish patients with osteoporosis at high risk of fracture: OSARIDELPHI study
Authors
Luis Arboleya
Jose Manuel Cancio-Trujillo
Celia Chaves
Enric Duaso-Magaña
Manuel Mesa-Ramos
Jose Manuel Olmos
Publication date
01-12-2023
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2023
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-023-01318-7

Other articles of this Issue 1/2023

Archives of Osteoporosis 1/2023 Go to the issue

Original Article

Incident vertebral fracture and longitudinal BMD change in Chinese postmenopausal women with early CKD: Peking Vertebral Fracture Study

Original Article

The association of osteoporosis and geriatric syndromes in the elderly: data from the Russian epidemiological study EVKALIPT

Original Article

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial

Original Article

Clinical profile, risk factors and functional outcomes in women and men presenting with hip fractures in KwaZulu-Natal, South Africa

Review Article

LRP5 high bone mass (Worth-type autosomal dominant endosteal hyperostosis): case report and historical review of the literature

Correction

Correction: Osteoporosis and vitamin D consumption: knowledge and practice in different Arab countries